{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:46:07Z","timestamp":1791873967281,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011382","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000}}],"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1239831"],"award-info":[{"award-number":["HDTRA1239831"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>This systematic review and network meta-analysis (NMA) aimed to compare the efficacy of all available treatments for severe melioidosis in decreasing hospital mortality and to identify eradication therapies with low disease recurrence rates and minimal risk of adverse drug events (AEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methodology<\/jats:title>\n<jats:p>Relevant randomized controlled trials (RCT) were searched from Medline and Scopus databases from their inception until July 31, 2022. RCTs that compared the efficacy between treatment regimens for severe melioidosis or eradication therapy of melioidosis, measured outcomes of in-hospital mortality, disease recurrence, drug discontinuation, or AEs, were included for review. A two-stage NMA with the surface under the cumulative ranking curve (SUCRA) was used to estimate the comparative efficacy of treatment regimens.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Principal findings<\/jats:title>\n<jats:p>Fourteen RCTs were included in the review. Ceftazidime plus granulocyte colony-stimulating factor (G-CSF), ceftazidime plus trimethoprim-sulfamethoxazole (TMP-SMX), and cefoperazone-sulbactam plus TMP-SMX had a lower mortality rate than other treatments and were ranked as the top three most appropriate treatments for severe melioidosis with the SUCRA of 79.7%, 66.6%, and 55.7%, respectively. However, these results were not statistically significant. For eradication therapy, treatment with doxycycline monotherapy for 20 weeks was associated with a significantly higher risk of disease recurrence than regimens containing TMP-SMX (i.e.,TMP-SMX for 20 weeks, TMP-SMX plus doxycycline plus chloramphenicol for more than 12 weeks, and TMP-SMX plus doxycycline for more than 12 weeks). According to the SUCRA, TMP-SMX for 20 weeks was ranked as the most efficacious eradication treatment (87.7%) with the lowest chance of drug discontinuation (86.4%), while TMP-SMX for 12 weeks had the lowest risk of AEs (95.6%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our results found a non-significant benefit of ceftazidime plus G-CSF and ceftazidime plus TMP-SMX over other treatments for severe melioidosis. TMP-SMX for 20 weeks was associated with a lower recurrence rate and minimal risk of adverse drug events compared to other eradication treatments. However, the validity of our NMA may be compromised by the limited number of included studies and discrepancies in certain study parameters. Thus, additional well-designed RCTs are needed to improve the therapy of melioidosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0011382","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T17:31:59Z","timestamp":1686591119000},"page":"e0011382","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of drug treatment for severe melioidosis and eradication treatment of melioidosis: A systematic review and network meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-8536","authenticated-orcid":true,"given":"Thunyarat","family":"Anothaisintawee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krit","family":"Harncharoenkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamonporn","family":"Poramathikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittijarankon","family":"Phontham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parat","family":"Boonyarangka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worachet","family":"Kuntawunginn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Boudreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Livezey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narisara","family":"Chantratita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"pntd.0011382.ref001","unstructured":"Centers for Disease Control and Prevention. Melioidosis: Bioterrorism Response Planning [cited 2023 19th April]. Available from: https:\/\/www.cdc.gov\/melioidosis\/bioterrorism-response-planning\/healthcare-response-activities.html."},{"issue":"6","key":"pntd.0011382.ref002","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.2010.10-0038","article-title":"Increasing incidence of human melioidosis in Northeast Thailand","volume":"82","author":"D Limmathurotsakul","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0011382.ref003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/bmb\/ldr007","article-title":"Melioidosis: a clinical overview","volume":"99","author":"D Limmathurotsakul","year":"2011","journal-title":"Br Med Bull"},{"issue":"2","key":"pntd.0011382.ref004","article-title":"Melioidosis in South Asia (India, Nepal, Pakistan, Bhutan and Afghanistan).","volume":"3","author":"C Mukhopadhyay","year":"2018","journal-title":"Trop Med Infect Dis"},{"issue":"2","key":"pntd.0011382.ref005","article-title":"Melioidosis in Africa: Time to Uncover the True Disease Load","volume":"3","author":"I Steinmetz","year":"2018","journal-title":"Trop Med Infect Dis"},{"issue":"12","key":"pntd.0011382.ref006","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S1473-3099(21)00022-0","article-title":"The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation","volume":"21","author":"BJ Currie","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"issue":"1","key":"pntd.0011382.ref007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/1471-2334-10-302","article-title":"Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia.","volume":"10","author":"MRA Hassan","year":"2010","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"pntd.0011382.ref008","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1128\/AAC.36.1.158","article-title":"Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis","volume":"36","author":"M Sookpranee","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"8665","key":"pntd.0011382.ref009","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(89)90768-X","article-title":"Halving of mortality of severe melioidosis by ceftazidime","volume":"2","author":"NJ White","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"pntd.0011382.ref010","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1086\/519261","article-title":"A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand","volume":"45","author":"AC Cheng","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0011382.ref011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1086\/320878","article-title":"Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis","volume":"33","author":"P Chetchotisakd","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"8","key":"pntd.0011382.ref012","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/444456","article-title":"Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis","volume":"41","author":"W Chierakul","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0011382.ref013","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/clinids\/19.5.846","article-title":"Ceftazidime vs. amoxicillin\/clavulanate in the treatment of severe melioidosis","volume":"19","author":"Y Suputtamongkol","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pntd.0011382.ref014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1099\/00222615-31-2-109","article-title":"Survival of Pseudomonas pseudomallei in human phagocytes","volume":"31","author":"S Pruksachartvuthi","year":"1990","journal-title":"J Med Microbiol"},{"issue":"8","key":"pntd.0011382.ref015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1086\/507632","article-title":"Risk factors for recurrent melioidosis in northeast Thailand","volume":"43","author":"D Limmathurotsakul","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0011382.ref016","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/infdis\/168.5.1181","article-title":"Relapse in Melioidosis: Incidence and Risk Factors","volume":"168","author":"W Chaowagul","year":"1993","journal-title":"The Journal of Infectious Diseases"},{"key":"pntd.0011382.ref017","volume-title":"Melioidosis: A Century of Observation and Research.","author":"N Ketheesan","year":"2012"},{"issue":"10","key":"pntd.0011382.ref018","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.49.10.4020-4025.2005","article-title":"Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis","volume":"49","author":"W Chaowagul","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"9919","key":"pntd.0011382.ref019","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(13)61951-0","article-title":"Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.","volume":"383","author":"P Chetchotisakd","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"pntd.0011382.ref020","article-title":"Melioidosis: An Australian Perspective.","volume":"3","author":"S Smith","year":"2018","journal-title":"Trop Med Infect Dis"},{"issue":"11","key":"pntd.0011382.ref021","doi-asserted-by":"crossref","first-page":"e3627","DOI":"10.1093\/cid\/ciaa1084","article-title":"A Comparison Between 12 Versus 20 Weeks of Trimethoprim-sulfamethoxazole as Oral Eradication Treatment for Melioidosis: An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial","volume":"73","author":"S Anunnatsiri","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pntd.0011382.ref022","first-page":"Cd001263","article-title":"Interventions for treating melioidosis.","author":"M Samuel","year":"2001","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"pntd.0011382.ref023","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.","volume":"42","author":"MH Abdul-Aziz","year":"2016","journal-title":"Intensive Care Medicine."},{"key":"pntd.0011382.ref024","article-title":"Chapter 11: Undertaking network meta-analyses.","author":"A Chaimani","year":"2022","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions version 63: Cochrane"},{"issue":"11","key":"pntd.0011382.ref025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"B Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"pntd.0011382.ref026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jrsm.1188","article-title":"The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis.","volume":"7","author":"D Jackson","year":"2016","journal-title":"Research Synthesis Methods"},{"issue":"2","key":"pntd.0011382.ref027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.","volume":"3","author":"JPT Higgins","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"1\u20132","key":"pntd.0011382.ref028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2001.64.24","article-title":"Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline","volume":"64","author":"P Chetchotisakd","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0011382.ref029","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1086\/520218","article-title":"A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis","volume":"29","author":"W Chaowagul","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0011382.ref030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0035-9203(95)90104-3","article-title":"A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis","volume":"89","author":"A Rajchanuvong","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"pntd.0011382.ref031","first-page":"265","article-title":"Cefoperazone\/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study.","volume":"81","author":"S Thamprajamchit","year":"1998","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"pntd.0011382.ref032","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/520219","article-title":"Comparison of imipenem and ceftazidime as therapy for severe melioidosis","volume":"29","author":"AJ Simpson","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pntd.0011382.ref033","doi-asserted-by":"crossref","first-page":"e0003586","DOI":"10.1371\/journal.pntd.0003586","article-title":"Intravenous Therapy Duration and Outcomes in Melioidosis: A New Treatment Paradigm.","volume":"9","author":"MC Pitman","year":"2015","journal-title":"PLOS Neglected Tropical Diseases."},{"key":"pntd.0011382.ref034","unstructured":"Ministry of Public Health DoCD. Guideline of Melioidosis Nonthaburi: Ministry of Public Health, Division of Communicable Disease; 2021 [cited 2023 6th March]. Available from: http:\/\/klb.ddc.moph.go.th\/dataentry\/handbook\/form\/129."},{"issue":"4","key":"pntd.0011382.ref035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/cp.1999.v66.a101210","article-title":"Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions","volume":"66","author":"T Hartung","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"pntd.0011382.ref036","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/380456","article-title":"Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis","volume":"38","author":"AC Cheng","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pntd.0011382.ref037","first-page":"29","article-title":"A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia","volume":"10","author":"P Hartmann","year":"2005","journal-title":"Eur J Med Res"},{"issue":"2","key":"pntd.0011382.ref038","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.CCM.0B013E318161E480","article-title":"Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock","volume":"36","author":"DP Stephens","year":"2008","journal-title":"Critical Care Medicine"},{"issue":"1","key":"pntd.0011382.ref039","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc10031","article-title":"Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.","volume":"15","author":"L Bo","year":"2011","journal-title":"Critical Care"},{"issue":"9","key":"pntd.0011382.ref040","doi-asserted-by":"crossref","first-page":"e0008659","DOI":"10.1371\/journal.pntd.0008659","article-title":"2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift","volume":"14","author":"RP Sullivan","year":"2020","journal-title":"PLOS Neglected Tropical Diseases"},{"issue":"1","key":"pntd.0011382.ref041","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/33.1.145","article-title":"Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies","volume":"33","author":"MD Smith","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"pntd.0011382.ref042","unstructured":"A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis (ATOM) [cited 2023 22 March]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00579956."},{"issue":"8","key":"pntd.0011382.ref043","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/CCM.0000000000001668","article-title":"Melioidosis Causing Critical Illness: A Review of 24 Years of Experience From the Royal Darwin Hospital ICU.","volume":"44","author":"DP Stephens","year":"2016","journal-title":"Crit Care Med."},{"issue":"3","key":"pntd.0011382.ref044","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0035-9203(00)90333-X","article-title":"Melioidosis: acute and chronic disease, relapse and re-activation","volume":"94","author":"BJ Currie","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011382","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T23:35:12Z","timestamp":1687649712000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011382"}},"subtitle":[],"editor":[{"given":"Husain","family":"Poonawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011382","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0011382","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}